Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03680521 trial: what clinicians have said so far
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
- NCT03680521 ↗
- Completed
- Mirati Therapeutics Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03680521 (sitravatinib plus nivolumab in locally advanced clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03680521 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Sitravatinib; Nivolumab
- Arms
- Sitravatinib and nivolumab · Experimental
- Enrollment
- 25
- Primary outcomes
- Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery
- Point in Time Objective Response Prior to Surgery
- Sponsor
- Mirati Therapeutics Inc.
- Start
- Oct 10, 2018
- Primary completion
- Apr 27, 2020
- Results posted
- Yes
- Registry record
- NCT03680521 · updated Oct 4, 2023